Study summary

A multicenter, randomized, double-blind, placebo-controlled, phase 2 study with a 1:1 randomization scheme.

Additional Study Details

Phase
2
Product
  • OSI-906
  • erlotinib
  • placebo
  • Type
    Interventional
    Masking
    Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
    Enrollment number
    205
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): English

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for Phase 2 study of Maintenance OSI-906 plus Erlotinib (Tarceva®), or Placebo plus Erlotinib in patients with nonprogression following 4 cycles of platinum-based chemotherapy? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Site RO40006
      Craiova, Romania, 200535
      Completed
      Site RU70011
      Saint Petersburg, Russian Federation, 197089
      Completed
      Site DE49005
      Minden, Germany, 32429
      Completed
      Site BR55016
      Goiania, Brazil, 74605-030
      Completed
      Site CA11001
      Oshawa, Canada, L1G 2B9
      Completed
      Site BR55015
      Cachoeiro de Itapemirim, Brazil, 29308-014
      Withdrawn
      Site RU70001
      Moscow, Russian Federation, 129128
      Completed
      Site KR82002
      Seoul, Republic of Korea, 137-701
      Completed
      Site PL48005
      Szczecin, Poland, 70-891
      Withdrawn
      Site US10006
      Buffalo, NY, United States, 14215
      Completed
      Site US10004
      Greensboro, NC, United States, 27403
      Completed
      Site BR55005
      Barretos, Brazil, 14784-400
      Completed
      Site GB44005
      London, United Kingdom, NW1 2PQ
      Withdrawn
      Site CA11003
      Montreal, Canada, H2W 1S6
      Completed
      Site CA11004
      Ottawa, Canada, K1H 8L6
      Completed
      Site US10011
      Scarborough, ME, United States, 04074
      Completed
      Site BR55006
      Ijui, Brazil, 98700-000
      Completed
      Site BR55003
      Fortaleza, Brazil, 60336-550
      Completed
      Site DE49015
      Kassel, Germany, 34125
      Completed
      Site KR82003
      Seoul, Republic of Korea, 120-752
      Completed
      Site PL48002
      Elblag, Poland, 82-300
      Completed
      Site GB44001
      Manchester, United Kingdom, M20 4BX
      Completed
      Site DE49009
      Homburg/Saar, Germany, 66421
      Completed
      Site PL48008
      Torun, Poland, 87-100
      Withdrawn
      Site CA11008
      Montreal, Canada, H2W 1S6
      Completed
      Site US10002
      Albany, GA, United States, 31701
      Completed
      Site BR55013
      Porto Alegre, Brazil, 90430-090
      Completed
      Site US10001
      Port St. Lucie, FL, United States, 34952
      Completed
      Site RO40001
      Baia Mare, Romania, 490110
      Completed
      Site RO40005
      Alba Iulia, Romania, 510077
      Completed
      Site BR55011
      Florianopolis, Brazil, 88034-000
      Completed
      Site GB44003
      Leeds, United Kingdom, LS9 7TF
      Withdrawn
      Site RU70004
      Saint Petersburg, Russian Federation, 197758
      Completed
      Site DE49008
      Koln, Germany, 51109
      Completed
      Site BR55001
      Itajai, Brazil, 88301-220
      Completed
      Site DE49013
      Mainz, Germany, 55131
      Completed
      Site DE49002
      Hemer, Germany, 58675
      Completed
      Site DE49001
      Heidelberg, Germany, 69126
      Completed
      Site KR82008
      Incheon, Republic of Korea, 400-711
      Completed
      Site CA11006
      Toronto, Canada, M5G 1X5
      Completed
      Site RO40003
      Cluj-Napoca, Romania, 400015
      Completed
      Site KR82004
      Seongnam-si, Republic of Korea, 463-707
      Completed
      Site RO40004
      Hunedoara, Romania, 331057
      Completed
      Site CA11002
      Toronto, Canada, M6R 1B5
      Withdrawn
      Site PL48004
      Warsaw, Poland, 02-781
      Completed
      Site KR82005
      Seoul, Republic of Korea, 135-710
      Completed
      Site KR82001
      Suwon, Republic of Korea
      Completed
      Site BR55012
      Ribeirao Preto, Brazil, 14515-130
      Completed
      Site BR55004
      Brasilia, Brazil, 70840-050
      Completed
      Site RU70009
      Saint Petersburg, Russian Federation, 197089
      Completed
      Site GB44002
      Leicester, United Kingdom, LE1 5WW
      Withdrawn
      Site PL48003
      Warszawa, Poland, 01-138
      Withdrawn
      Site BR55009
      Londrina, Brazil, 86050-190
      Completed
      Site DE49014
      Berlin, Germany, 10117
      Completed
      Site DE49012
      Karlsruhe, Germany, 76137
      Completed
      Site BR55014
      Porto Alegre, Brazil, 90610-000
      Completed
      Site GB44006
      Dundee, United Kingdom, DD1 9SY
      Completed
      Site KR82007
      Busan, Republic of Korea, 602-715
      Completed
      Site RU70007
      Saint Petersburg, Russian Federation, 194291
      Completed
      Site DE49003
      Grosshansdorf, Germany, 22977
      Completed
      Site RO40007
      Brasov, Romania, 500366
      Completed
      Site GB44007
      Bristol, United Kingdom, BS2 8ED
      Completed
      Site DE49011
      Dortmund, Germany, 44145
      Completed
      Site RO40002
      Cluj-Napoca, Romania, 400015
      Completed
      Site DE49006
      Immenhausen, Germany, 34376
      Completed
      Site US10010
      Winston-Salem, NC, United States, 27103
      Completed
      Site KR82006
      Hwasun, Republic of Korea, 519-809
      Completed
      Site GB44004
      Southampton, United Kingdom, SO16 6YD
      Completed
      Site RU70010
      Kazan, Russian Federation, 420029
      Completed
      Site BR55002
      Rio de Janeiro, Brazil, 20231-050
      Completed
      Site US10007
      Jacksonville, FL, United States, 32207
      Completed
      Site RU70002
      Chelaybinsk, Russian Federation, 454087
      Completed
      Site PL48006
      Wroclaw, Poland, 53-439
      Completed
      Site BR55008
      Piracicaba, Brazil, 13419-155
      Withdrawn
      Site US10005
      Morristown, NJ, United States, 07962-1089
      Completed
      Site BR55007
      Sao Paulo, Brazil, 01323-920
      Completed
      Site US10008
      Chicago, IL, United States, 60612
      Withdrawn
      Site CA11007
      Montreal, Canada, H2W 1S6
      Withdrawn
      Site RU70008
      Nizhniy Novgorod, Russian Federation, 603081
      Completed
      Site DE49010
      Lubeck, Germany, 23538

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?